Quantcast
Last updated on April 16, 2014 at 5:49 EDT

Latest gastrointestinal stromal tumor Stories

2010-12-02 05:00:00

NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved SUTENT® (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as initial treatment is limited in this disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.(1,2)...

2010-09-27 16:01:00

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT® (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer (CRPC) that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee (DMC) found that the combination of sunitinib with...

2010-08-23 16:01:00

NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE :PFE) announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Overall survival was the primary endpoint of the study and Progression-Free Survival was a secondary endpoint of the study. No new or...

2010-06-24 15:07:47

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. However, the duodenal location is less common. Nowadays, surgery is still the only curative approach for GIST. Numerous procedures can be performed to remove duodenal GIST. Some of these operations are extensive and require difficult reconstruction (like pancreaticoduodenectomy; PD). One of the options is a more limited intervention: segmental duodenectomy (SD). However, few studies have...

2010-03-08 12:53:39

ESMO Conference on Sarcoma and GIST New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors. At the ESMO Conference on Sarcoma and GIST, to be held in Milan, Italy, on 9 and 10 March 2010, researchers and some of the world's leading experts will discuss exciting new science on sarcomas"”a group of rare tumors found in muscle, blood vessels, deep skin tissues, nerves and the tissues around joints. Although...

2010-02-18 08:19:36

Researchers are able to predict and reverse resistance to a commonly used treatment Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer.  Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment. Kidney cancer is among the 10 most common cancers...

2010-01-11 15:47:00

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research. Bortezomib, or Velcade, is used to treat multiple myeloma and certain lymphomas, said Anette Duensing, M.D., assistant professor of...

2009-07-29 10:21:34

A research article to be published on July 21, 2009 in the World Journal of Gastroenterology addresses this question. This research led by Professor Kim and his colleagues in Pusan National University, South Korea. They evaluated the EUS features of gastric GISTs in comparison with gastric leiomyomas, and tried to determine the EUS features that could predict the malignant potential of gastric GISTs according to the histological risk classification.In their study, to differentiate GISTs from...

2009-07-16 16:42:57

Survival rate racial differences for gastrointestinal tumors are narrowing between African-Americans and whites, U.S. researchers said. The study, published in the Journal of the American College of Surgeons, found in the case of a rare cancer that begins in the wall of the gastrointestinal tract known as a gastrointestinal stromal tumor, the 30-day surgical mortality rate which was higher in African-Americans prior to the year 2000 has become equivalent in the last 10 years. Over the last...

2009-07-14 10:45:00

After years of inequality, survival rates now equivalent to those of CaucasiansNew research published in the July issue of the Journal of the American College of Surgeons reveals that African Americans with gastrointestinal stromal tumors (GIST), a rare cancer that begins in the wall of the gastrointestinal tract, now have survival rates equivalent to those of Caucasians. Prior to 2000, African Americans were more likely to develop GIST and less likely to undergo surgical treatment for this...